SUO 2020: Results from the PROfound Study, A New Second Line Therapy for mCRPC
(UroToday.com) In the second Prostate Cancer session at this year’s Society of Urologic Oncology virtual annual meeting, Dr. Maha Hussain discussed the role of poly ADP ribose polymerase (PARP) inhibitors, particularly olaparib, in metastatic castration-resistant prostate cancer.
Dr. Hussain began by reviewing the rationale for targeting PARP-1 in advanced prostate cancer given its implicated role in many aspects of prostate cancer including its role in mediating DNA repair response to alkylating agents, in cellular survival in BRCA deficient cells, and in androgen-receptor mediated prostate cancer cellular proliferation. Further, the Stand Up To Cancer (SU2C) project analysis demonstrated that more than 20% of patients with mCRPC harbor DNA repair pathway aberrations including BRCA2, BRCA1, ATM and many others of which 8-10% are pathogenic germline findings.